about
Leishmania donovani triose phosphate isomerase: a potential vaccine target against visceral leishmaniasisTh1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis.Syndecan-1 identifies and controls the frequency of IL-17-producing naïve natural killer T (NKT17) cells in mice.Comparative Analysis of Cellular Immune Responses in Treated Leishmania Patients and Hamsters against Recombinant Th1 Stimulatory Proteins of Leishmania donovani.Hexadecylphosphocholine (Miltefosine) stabilized chitosan modified Ampholipospheres as prototype co-delivery vehicle for enhanced killing of L. donovani.Development of Leishmania donovani stably expressing DsRed for flow cytometry-based drug screening using chalcone thiazolyl-hydrazone as a new antileishmanial target.Bioinspired Calcium Phosphate Nanoparticles Featuring as Efficient Carrier and Prompter for Macrophage Intervention in Experimental Leishmaniasis.Development of 4-sulfated N-acetyl galactosamine anchored chitosan nanoparticles: A dual strategy for effective management of Leishmaniasis.Chondroitin nanocapsules enhanced doxorubicin induced apoptosis against leishmaniasis via Th1 immune response.Targeted chemotherapy of visceral leishmaniasis by lactoferrin-appended amphotericin B-loaded nanoreservoir: in vitro and in vivo studies.Synergistic enhancement of parasiticidal activity of amphotericin B using copaiba oil in nanoemulsified carrier for oral delivery: an approach for non-toxic chemotherapyAntigen presenting cells targeting and stimulation potential of lipoteichoic acid functionalized lipo-polymerosome: a chemo-immunotherapeutic approach against intracellular infectious disease.Self assembled ionically sodium alginate cross-linked amphotericin B encapsulated glycol chitosan stearate nanoparticles: applicability in better chemotherapy and non-toxic delivery in visceral leishmaniasis.Chitosan-assisted immunotherapy for intervention of experimental leishmaniasis via amphotericin B-loaded solid lipid nanoparticles.Syndecan-1-coating of interleukin-17-producing natural killer T cells provides a specific method for their visualization and analysis.Chitosan coated PluronicF127 micelles for effective delivery of Amphotericin B in experimental visceral leishmaniasis.Immunoprotective responses of T helper type 1 stimulatory protein-S-adenosyl-L-homocysteine hydrolase against experimental visceral leishmaniasis.Overexpressed Macrophage Mannose Receptor Targeted Nanocapsules- Mediated Cargo Delivery Approach for Eradication of Resident Parasite: In Vitro and In Vivo Studies.Immunological consequences of stress-related proteins--cytosolic tryparedoxin peroxidase and chaperonin TCP20--identified in splenic amastigotes of Leishmania donovani as Th1 stimulatory, in experimental visceral leishmaniasis.Identification of novel S-adenosyl-L-homocysteine hydrolase inhibitors through homology-model-based virtual screening, synthesis, and biological evaluation.Efficacy of Leishmania donovani trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis.Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening.Exploitation of lectinized lipo-polymerosome encapsulated Amphotericin B to target macrophages for effective chemotherapy of visceral leishmaniasis.Covalent functionalized self-assembled lipo-polymerosome bearing amphotericin B for better management of leishmaniasis and its toxicity evaluation.Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.Development and evaluation of tripalmitin emulsomes for the treatment of experimental visceral leishmaniasis.Design and development of Amphotericin B bearing polycaprolactone microparticles for macrophage targeting.Development and characterization of doxorubicin loaded microparticles against experimental visceral leishmaniasisTh-1 biased immunomodulation and synergistic antileishmanial activity of stable cationic lipid-polymer hybrid nanoparticle: biodistribution and toxicity assessment of encapsulated amphotericin B
P50
Q28483976-9B9B32C8-D572-4E46-AA18-AD2A12FAF5D4Q34277331-6A9F9106-68C0-4DB5-86D0-373ECAB16F15Q36365809-E7E91826-A539-4724-BDF4-DB5759805778Q36712429-C8980BEC-0003-4A45-BF36-96B5A06A8502Q38674942-CC7609FF-1B66-4A3A-A897-758927AE218FQ38729596-E5A06A53-A863-4725-A76B-F5BD7ADF65ACQ38758771-D970CC44-B905-4DDF-9AEB-9F3B6664AFDAQ38834615-68BA2294-E0BF-4D1A-8BDD-806267D08334Q38880281-925B108C-2F4C-4A60-99FD-0A038AB35634Q38880433-6C9C7758-E6C7-408C-B3F7-0CA583688EE7Q38892819-CEE52198-0934-4753-82A4-B54E88F4AABBQ38910793-4E1A60CD-3FD0-40E8-90A2-8D889EB28E58Q38937745-4ED84256-42B5-4DA8-AB8D-2F868C0AF9AFQ38967744-A32EAF26-4D96-4D33-8EDD-3910A304A17CQ39279449-8CFA352B-D5A6-475C-9331-E8E3DBD51E3FQ40105242-9723FF99-8C39-4E6C-A2DA-97027BD5092AQ40783439-037EBF71-1DC0-404E-AA9D-28BF013CED55Q41464018-4EECCD59-E30D-4FEF-B1EE-048BC8DE45BFQ41603970-9BAACE88-A228-4959-8CF0-F7DEBBF3C5E2Q44993371-3148038B-1BA9-4852-BD5A-0D7D0D738E86Q46290224-3EDF105B-255F-47DB-9FF2-52356F9F33A7Q50591086-8A8D00C6-2A65-4D69-8A50-1098B0C497BFQ51748659-B9CCEB30-87E0-4ED4-9D25-BBD74927FF61Q51750249-317B857E-68D9-4BEA-98B0-3404DCF50BB9Q51763528-A034FD67-CB43-4424-B5DC-2E5FD06656E9Q51766744-4E6E7D74-C8E2-4ADB-992B-85F8A72137B0Q51768535-3904C57F-75C8-4EB4-B03C-B63FF2519C4FQ83839567-03B28A35-D4BD-429C-9C83-F060A4FB0456Q86191485-D3BC7316-760C-409C-BC47-91705B258BB5
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Anil K Jaiswal
@ast
Anil K Jaiswal
@en
Anil K Jaiswal
@es
Anil K Jaiswal
@nl
Anil K Jaiswal
@sl
type
label
Anil K Jaiswal
@ast
Anil K Jaiswal
@en
Anil K Jaiswal
@es
Anil K Jaiswal
@nl
Anil K Jaiswal
@sl
prefLabel
Anil K Jaiswal
@ast
Anil K Jaiswal
@en
Anil K Jaiswal
@es
Anil K Jaiswal
@nl
Anil K Jaiswal
@sl
P106
P31
P496
0000-0002-8169-0335